AR058855A1 - Compuestos heterociclicos que se unen a proteinas bcl inhibiendo su funcion, composiciones farmaceuticas que los contienen y usos para el tratamiento del cancer - Google Patents
Compuestos heterociclicos que se unen a proteinas bcl inhibiendo su funcion, composiciones farmaceuticas que los contienen y usos para el tratamiento del cancerInfo
- Publication number
- AR058855A1 AR058855A1 ARP060105561A ARP060105561A AR058855A1 AR 058855 A1 AR058855 A1 AR 058855A1 AR P060105561 A ARP060105561 A AR P060105561A AR P060105561 A ARP060105561 A AR P060105561A AR 058855 A1 AR058855 A1 AR 058855A1
- Authority
- AR
- Argentina
- Prior art keywords
- independently
- heteroaryl
- heterocyclyl
- aryl
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
Abstract
Reivindicacion 1: Un compuesto representado por la formula (1): o una sal farmacéuticamente aceptable del mismo; en la cual Y es -C(R10)2-, -(C=O)-, -(C=S)-, o -C(=NR10)-; X es -N(R10)- o un enlace; m es 0, 1, 2, 3, 4, 5 o 6; cada uno de A1 y A2 es independientemente H, alquilo, alquenilo, alquinilo, arilo, cicloalquilo, aralquilo, heterociclilo, heteroarilo, heteroaralquilo, -C(O)N(R10)2, -C(O)R10, -CO2R10, -S(O)2N(R10)2, -S(O)R10, -S(O)2OR10, -S(O)2R10; o tiene la formula -(C(R10)2)n-R15: en la cual, independientemente para cada ocurrencia n es 1, 2, 3, 4, 5 o 6; R15 es arilo, cicloalquilo, cicloalquenilo, heterociclilo, heteroarilo, -OR10, -SR10, -N(R10)2, -N(R10)CO2R10, -N(R10)C(O)N(R10)2, -CO2R10 o -C(O)N(R10)2; o es un anillo policíclico que contiene C8-14, del cual por lo menos uno, dos o tres átomos del anillo son independientemente S, O o N; o A1 y A2 tomados conjuntamente forman =O o =S; o A1 y A2 tomados conjuntamente con el carbono al cual están unidos forman un heterociclilo de 5 a 8 miembros, del cual uno o dos átomos del anillo son independientemente S, O o N; B es O, S, -(C=O)-, -(C=S)- o es un resto de formula (2); o tiene la formula (3): en la cual D es N o CR10; p es 0, 1, 2, 3, 4 o 5; cada uno de R7 y R8 es, independientemente para cada ocurrencia, H, alquilo, alquenilo, alquinilo, aralquilo, arilo, cicloalquilo, heterociclilo, cicloalquenilo o heteroarilo; o R7 y R8 tomados conjuntamente forman un anillo de 3-8 miembros; o R7 y R8 tomados conjuntamente forman un anillo de 4-8 miembros; R9 es H, heterociclilo, heteroarilo, -OR10, -SR10, -N(R10)2, -N(R10)CO2R10, -N(R10)C(O)N(R10)2, -CO2R10, -OCO2R10, -OC(O)N(R10)2, -C(O)N(R10)2, haluro, nitrilo, nitro o aciltio; R1 tiene la formula (4): en la cual q es 0, 1, 2, 3, 4 o 5; r es 0, 1, 2, 3, 4 o 5; Ar1 es un arilo monocíclico o bicíclico con 6-14 átomos en el anillo; o un heteroarilo monocíclico o bicíclico con 5-14 átomos en el anillo, del cual uno, dos o tresátomos del anillo son independientemente S, O o N; o Ar1 está representado por la formula (5): en la cual s es 0, 1, 2, 3 o 4; cada uno de X2 y X3 es, independientemente para cada ocurrencia, H, alquilo, alquenilo, alquinilo, arilo, cicloalquilo, heterociclilo, aralquilo, heteroarilo, heteroaralquilo, hidroxilo, aciloxi, nitrilo, nitro, haluro, OR11, -C(O)N(R10)(R11), -C(O)R11, -CO2R11, -S(O)2N(R10)(R11), SR11, -S(O)R11, -S(O)2OR11, -S(O)2R11, -C(=NR10)N(R10)(R11) o -C(=NR10)(R11); o tiene la formula - (C(R10)2)n-R15; Ar2 es un arilo monocíclico o bicíclico con 6-14 átomos en el anillo; o un heteroarilo monocíclico o bicíclico con 5-14 átomos en el anillo, del cual uno, dos o tres átomos del anillo son independientemente S, O o N; X1 es un enlace, -C(R10)2-, -S-, -(NR10)- o -O-; R2 es H, un alquilo o alquenilo ramificado o no ramificado, cicloalquilo, heterociclilo o bicicloalquilo; o tiene la formula -(C(R10)2)n-R15; R3 es H, heterociclilo, heteroarilo, -OR10, -SR10, -N(R10)2, -N(R10)CO2R10, -N(R10)C(O)N(R10)2, -CO2R10, -OCO2R10, -OC(O)N(R10)2, -C(O)N(R10)2, haluro, nitrilo, nitro o aciltio; cada uno de R4, R5 y R10, independientemente para cada ocurrencia, es H, alquilo, alquenilo, alquinilo, aralquilo, arilo, cicloalquilo, cicloalquenilo, bicicloalquilo, heterociclilo o heteroarilo; o tiene la formula -(C(R10)2)n-R15; o cualesquiera dos casos de R10 tomados conjuntamente forman un anillo de 3-8 miembros; o R4 y R5 tomados conjuntamente forman un anillo de 3-8 miembros; R6 es H o alquilo; R11 es, independientemente para cada ocurrencia, H, alquilo, alquenilo, alquinilo, aralquilo, arilo, cicloalquilo, cicloalquenilo, bicicloalquilo, heterociclilo, heteroarilo o -[C(R12)(R13)]t-R14; en donde t es 0, 1, 2, 3, 4 o 5; cada uno de R12 y R13 es independientemente para cada ocurrencia, H, alquilo, arilo, aralquilo, cicloalquilo, heterociclilo, heterociclilalquilo, heteroarilo o heteroaralquilo; yR14 es independientemente para cada ocurrencia, H, alquilo, arilo, heteroarilo, heterociclilalquilo, alcoxi, amino, amido, o carboxilo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75098705P | 2005-12-16 | 2005-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR058855A1 true AR058855A1 (es) | 2008-02-27 |
Family
ID=38024107
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060105561A AR058855A1 (es) | 2005-12-16 | 2006-12-15 | Compuestos heterociclicos que se unen a proteinas bcl inhibiendo su funcion, composiciones farmaceuticas que los contienen y usos para el tratamiento del cancer |
Country Status (27)
Country | Link |
---|---|
US (2) | US7745464B2 (es) |
EP (1) | EP1973875B1 (es) |
JP (1) | JP5341521B2 (es) |
KR (1) | KR101373911B1 (es) |
CN (1) | CN101374807B (es) |
AR (1) | AR058855A1 (es) |
AU (1) | AU2006329879B2 (es) |
BR (1) | BRPI0619968A2 (es) |
CA (1) | CA2633958C (es) |
EC (1) | ECSP088607A (es) |
ES (1) | ES2494765T3 (es) |
HK (1) | HK1119704A1 (es) |
IL (1) | IL192023A (es) |
JO (1) | JO2918B1 (es) |
MA (1) | MA30144B1 (es) |
MX (1) | MX2008007687A (es) |
MY (1) | MY153232A (es) |
NO (1) | NO20083050L (es) |
NZ (1) | NZ569660A (es) |
PE (1) | PE20071033A1 (es) |
RU (1) | RU2424230C2 (es) |
SA (1) | SA06270462B1 (es) |
SG (1) | SG170727A1 (es) |
TN (1) | TNSN08258A1 (es) |
TW (1) | TWI403320B (es) |
WO (1) | WO2007075387A1 (es) |
ZA (1) | ZA200805822B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7842815B2 (en) * | 2004-06-17 | 2010-11-30 | Infinity Pharmaceuticals, Inc. | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
TWI389895B (zh) * | 2006-08-21 | 2013-03-21 | Infinity Discovery Inc | 抑制bcl蛋白質與結合夥伴間之交互作用的化合物及方法 |
CN103450077B (zh) | 2007-06-08 | 2016-07-06 | 满康德股份有限公司 | IRE-1α抑制剂 |
CN101906056B (zh) * | 2009-06-04 | 2013-10-30 | 中国科学院广州生物医药与健康研究院 | 作为m2抑制剂的环烷胺类化合物及其应用 |
US8314250B2 (en) * | 2009-11-24 | 2012-11-20 | Hoffmann-La Roche Inc. | Sultam derivatives |
US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
FR3048698B1 (fr) * | 2016-03-11 | 2021-03-05 | Univ Claude Bernard Lyon | Inhibiteurs de l'interaction bcl2 l10 / recepteur ip3 |
WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
JP2021050161A (ja) | 2019-09-25 | 2021-04-01 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
JP2021080177A (ja) | 2019-11-14 | 2021-05-27 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5053548A (en) | 1989-02-08 | 1991-10-01 | Otsuka Pharmaceutical Company, Ltd. | Biphenyl derivative composition for nerve cell degeneration repairing or protective agent and process for preparing a phenyl derivative contained in the composition |
BR9408137A (pt) | 1993-11-24 | 1997-08-12 | Du Pont Merck Pharma | Composto éster de prodroga método de tratamento composição farmacêutica e método de inibição |
US6693123B2 (en) * | 1995-11-06 | 2004-02-17 | University Of Pittsburgh | Inhibitors of protein isoprenyl transferases |
KR100399361B1 (ko) | 1999-11-04 | 2003-09-26 | 주식회사 엘지생명과학 | 캐스파제 억제제 함유 치료제 조성물 |
EP1125925A1 (en) * | 2000-02-15 | 2001-08-22 | Applied Research Systems ARS Holding N.V. | Amine derivatives for the treatment of apoptosis |
SI1268418T1 (sl) * | 2000-03-27 | 2006-10-31 | Applied Research Systems | Farmacevtsko aktivni pirolidinski derivati kot bax-inhibitorji |
WO2002013833A2 (en) | 2000-08-16 | 2002-02-21 | Georgetown University Medical Center | SMALL MOLECULE INHIBITORS TARGETED AT Bcl-2 |
US7795232B1 (en) | 2000-08-25 | 2010-09-14 | Genta Incorporated | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
US7855183B2 (en) | 2000-11-10 | 2010-12-21 | Genta Incorporated | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
US20040147473A1 (en) | 2000-11-10 | 2004-07-29 | Warrell Raymond P. | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
KR20040108528A (ko) | 2001-05-30 | 2004-12-24 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Bcl2 군 단백질의 소분자 길항제 |
US20030119894A1 (en) | 2001-07-20 | 2003-06-26 | Gemin X Biotechnologies Inc. | Methods for treatment of cancer or neoplastic disease and for inhibiting growth of cancer cells and neoplastic cells |
US20050026929A1 (en) * | 2002-04-23 | 2005-02-03 | Axys Pharmaceuticals, Inc. | Novel phenyl derivatives as inducers of apoptosis |
US20050256157A1 (en) * | 2002-08-23 | 2005-11-17 | Chiron Corporation | Combination therapy with CHK1 inhibitors |
KR20050058507A (ko) * | 2002-09-04 | 2005-06-16 | 쉐링 코포레이션 | 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘 |
CN100364531C (zh) * | 2002-12-18 | 2008-01-30 | 西托维亚公司 | 3,5-二取代-[1,2,4]-二唑及类似物和其用途 |
WO2004099158A1 (en) * | 2003-04-30 | 2004-11-18 | Ricerca Biosciences, Llc. | Monocyclic diazodioxide based bcl-2 protein antagonists |
US7585878B2 (en) * | 2003-06-12 | 2009-09-08 | Astellas Pharma Inc. | Benzamide derivative or salt thereof |
CA2541100A1 (en) * | 2003-09-16 | 2005-03-24 | Astrazenca Ab | Quinazoline derivatives |
CA2548326A1 (en) * | 2003-12-23 | 2005-07-14 | Novartis Ag | Bicyclic heterocyclic p-38 kinase inhibitors |
TW200528101A (en) * | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
ATE548359T1 (de) | 2004-06-17 | 2012-03-15 | Infinity Discovery Inc | Verbindungen und verfahren zur inhibierung der wechselwirkung von bcl-proteinen mit bindungspartnern |
JPWO2006025360A1 (ja) | 2004-08-30 | 2008-05-08 | 三菱レイヨン株式会社 | 光学用共重合体及びそれからなる成形体 |
PE20060748A1 (es) * | 2004-09-21 | 2006-10-01 | Smithkline Beecham Corp | Derivados de indolcarboxamida como inhibidores de quinasa ikk2 |
US7759337B2 (en) * | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
TW200803740A (en) | 2005-12-16 | 2008-01-16 | Du Pont | 5-aryl isoxazolines for controlling invertebrate pests |
-
2006
- 2006-11-30 TW TW095144471A patent/TWI403320B/zh not_active IP Right Cessation
- 2006-12-14 PE PE2006001602A patent/PE20071033A1/es not_active Application Discontinuation
- 2006-12-15 AR ARP060105561A patent/AR058855A1/es unknown
- 2006-12-15 ES ES06845504.7T patent/ES2494765T3/es active Active
- 2006-12-15 AU AU2006329879A patent/AU2006329879B2/en not_active Ceased
- 2006-12-15 MY MYPI20082026A patent/MY153232A/en unknown
- 2006-12-15 CN CN2006800528798A patent/CN101374807B/zh not_active Expired - Fee Related
- 2006-12-15 BR BRPI0619968-2A patent/BRPI0619968A2/pt not_active IP Right Cessation
- 2006-12-15 MX MX2008007687A patent/MX2008007687A/es active IP Right Grant
- 2006-12-15 WO PCT/US2006/047861 patent/WO2007075387A1/en active Application Filing
- 2006-12-15 SG SG201101864-5A patent/SG170727A1/en unknown
- 2006-12-15 US US11/640,480 patent/US7745464B2/en not_active Expired - Fee Related
- 2006-12-15 CA CA2633958A patent/CA2633958C/en not_active Expired - Fee Related
- 2006-12-15 EP EP06845504.7A patent/EP1973875B1/en active Active
- 2006-12-15 RU RU2008128569/04A patent/RU2424230C2/ru not_active IP Right Cessation
- 2006-12-15 NZ NZ569660A patent/NZ569660A/en not_active IP Right Cessation
- 2006-12-15 JP JP2008545837A patent/JP5341521B2/ja not_active Expired - Fee Related
- 2006-12-15 KR KR1020087017168A patent/KR101373911B1/ko not_active IP Right Cessation
- 2006-12-16 SA SA6270462A patent/SA06270462B1/ar unknown
- 2006-12-17 JO JO2006461A patent/JO2918B1/en active
-
2008
- 2008-06-10 IL IL192023A patent/IL192023A/en not_active IP Right Cessation
- 2008-06-13 TN TNP2008000258A patent/TNSN08258A1/en unknown
- 2008-07-03 ZA ZA200805822A patent/ZA200805822B/xx unknown
- 2008-07-04 MA MA31089A patent/MA30144B1/fr unknown
- 2008-07-07 EC EC2008008607A patent/ECSP088607A/es unknown
- 2008-07-07 NO NO20083050A patent/NO20083050L/no not_active Application Discontinuation
- 2008-12-08 HK HK08113302.8A patent/HK1119704A1/xx not_active IP Right Cessation
-
2010
- 2010-04-02 US US12/753,319 patent/US8304428B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR058855A1 (es) | Compuestos heterociclicos que se unen a proteinas bcl inhibiendo su funcion, composiciones farmaceuticas que los contienen y usos para el tratamiento del cancer | |
ES2589555T3 (es) | Compuestos de benceno sustituidos con arilo o heteroarilo | |
AR099955A1 (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados | |
AR083367A1 (es) | Compuestos de tipo quinazolinona como antagonistas de crth | |
AR106944A2 (es) | Compuestos de isoindolina y composiciones farmacéuticas de los mismos | |
AR085327A1 (es) | Inhibidores del virus de la hepatitis c | |
AR060545A1 (es) | Compuestos de benzoaxol y benzotiazol 6-0- sustituidos y metodos de inhibicion de la senalizacion de csf-1r. composiciones farmaceuticas | |
CO6241190A2 (es) | Compuestos para inhibicion enzimatica | |
AR084553A1 (es) | DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER | |
AR081649A1 (es) | Compuestos heteroarilo nitrogenados | |
AR091279A1 (es) | Inhibidores macrociclicos de virus flaviviridae | |
AR090398A1 (es) | Inhibidores heterociclicos de glutaminasa | |
BRPI0619823A8 (pt) | compostos que são inibidores de erk | |
AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
CO6321289A2 (es) | Compuestos de ester boronato y composiciones farmaceuticas de los mismos | |
AR087711A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y uso de los mismos para el tratamiento de trastornos neurodegenerativos | |
CO5261616A1 (es) | Inhibidores no peptidicos de la union celular dependientes de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias | |
CO4990929A1 (es) | Compuestos de difenilurea sustituidos con sulfonamidas como antagonistas de los receptores de il-8 | |
AR093758A1 (es) | Inhibidores de aril lactama quinasa | |
AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
AR090868A1 (es) | Composiciones plaguicidas y procesos relacionados con ellas | |
AR083946A1 (es) | Metodos de tratamiento con inhibidores selectivos de bcl-2 | |
AR081653A1 (es) | Inhibidores del virus de la hepatitis c | |
BR0114986A (pt) | Composto, composição farmacêutica, uso de pelo menos um composto ou um sal, solvato ou hidrato deste farmaceuticamente aceitáveis, e, processo para preparar triazolona partir de uma acil semicarbazida. | |
CO6150158A2 (es) | Piperidinas sustituidas que aumentan la actividad de p53 y su uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |